Alexander Spira, MD, PhD, FACP, FASCO

Alexander Spira, MD, PhD, FACP, FASCO, explains why sarcoma treatment lags behind other solid tumors and the access, subtype, and biomarker barriers.

Sarcoma's rarity and molecular diversity complicate trial design. Alexander Spira, MD, PhD, FACP, FASCO discusses biomarker testing, NGS panels, and referral gaps.

Alexander Spira, MD, PhD, FACP, FASCO, on why sarcoma diagnosis is often delayed and how community-academic collaboration speeds treatment.

Alexander Spira, MD, PhD, discusses why sarcoma treatment lags other cancers, citing tumor heterogeneity and inconsistent immunotherapy response as barriers.